Introduction

Intellectual property (IP) in biotechnology refers to the legal protection of inventions, biological technologies, genetic engineering methods, pharmaceutical products, diagnostic tools, microorganisms, plant varieties and commercially valuable scientific information. In China, biotechnology IP protection is essential for encouraging research, attracting investment, supporting technology transfer and preventing unauthorised commercial exploitation. The principal legal framework includes the Patent Law, Trademark Law, Copyright Law, Anti-Unfair Competition Law, Civil Code and specialised regulations governing new plant varieties and genetic resources.

Legal Framework for Biotechnology Intellectual Property

China's Patent Law protects inventions that satisfy statutory requirements of novelty, inventiveness and practical applicability. Eligible biotechnology inventions may include engineered microorganisms, production processes, pharmaceutical compounds, diagnostic technologies and certain genetically modified biological materials. However, discoveries of natural laws and naturally occurring substances merely discovered rather than technically invented do not automatically qualify for patent protection.

Article 25 excludes specified subject matter, including scientific discoveries, methods for diagnosing or treating diseases, and animal and plant varieties, subject to the distinct protection available under applicable laws. Microbiological processes and products obtained through such processes may qualify when the statutory requirements are satisfied. Article 26 requires sufficient disclosure of the invention in the patent specification so that a skilled person can implement it.

The Anti-Unfair Competition Law protects qualifying trade secrets against misappropriation. Biotechnology companies may use trade-secret protection for confidential manufacturing parameters, fermentation processes, experimental datasets and proprietary research methods. Unlike patents, trade-secret protection generally depends on maintaining secrecy and does not prevent lawful independent discovery.

Patent Protection for Biotechnology Inventions

Biotechnology patents present distinctive challenges because inventions may depend on living materials, genetic sequences and complex biological processes. Patent applicants must establish that their claims define an eligible technical invention and that the specification adequately explains how it can be reproduced.

Pharmaceutical inventions may require evidence supporting claimed technical effects. Engineered microorganisms may require adequate information about genetic modifications, deposited biological materials, cultivation conditions and product verification. Patent protection is also territorial, meaning a Chinese patent does not automatically provide equivalent protection in other jurisdictions.

Relevant Case Laws

1. Engineered Sphingomonas Patent Case (2024)

In Supreme People's Court case (2024) Zui Gao Fa Zhi Xing Zhong No. 1241, concerning an engineered Sphingomonas strain and its construction method and applications, the court considered whether the patent specification sufficiently disclosed the invention.

The dispute concerned whether the described genetic engineering and fermentation methods enabled a skilled person to reproduce the engineered strain and obtain the expected product. The Supreme People's Court upheld the validity decision, finding that the disclosed gene sequences, strain deposit information, plasmid construction methods, culture conditions and supporting evidence established reproducibility and sufficiently supported the claimed technical effects.

The case clarifies that biotechnology patent disclosure must be assessed in light of the characteristics of biological inventions. Adequate technical information and verifiable biological materials can establish enablement when considered together with the relevant scientific knowledge.

2. Patent Infringement and the Scientific Research Exception (2023)

In Supreme People's Court case (2023) Zui Gao Fa Zhi Min Zhong No. 1511, concerning pesticide patent rights and regulatory registration, the court considered the circumstances in which limited manufacture and use of a patented product for regulatory registration could fall within the scientific research exception under patent law.

The court recognised that limited use of a patented invention to generate necessary experimental data for regulatory approval may qualify for the exception where the applicable conditions are satisfied and the legitimate interests of the patent holder are not unreasonably harmed.

This principle is relevant to biotechnology because research and regulatory testing can require the use of patented technologies. However, the exception is limited and does not provide a general authorisation for ordinary commercial manufacturing or sales.

3. Patent Ownership Dispute Involving Biotechnology Companies

China's Supreme People's Court has addressed disputes over patent ownership between technology companies, including biotechnology enterprises. In such disputes, courts may examine invention records, employment relationships, research agreements, development contributions and the circumstances in which the invention was created.

These disputes demonstrate the importance of establishing ownership rights before licensing, commercialisation or investment. A company cannot assume that every invention developed using its facilities automatically belongs to it without considering the governing legal rules and contractual arrangements.

Trade Secrets and Confidential Research Information

Trade-secret protection is particularly important where biotechnology inventions depend on manufacturing knowledge that may be difficult to reverse-engineer. Confidential fermentation parameters, production optimisation methods, biological screening data and manufacturing protocols may qualify if they possess commercial value, are not generally known and are subject to reasonable confidentiality measures.

The Anti-Unfair Competition Law provides remedies against unlawful acquisition, disclosure or use of qualifying trade secrets. Biotechnology enterprises should establish confidentiality agreements, restrict access to sensitive information and maintain appropriate records of research contributions. Contractual confidentiality obligations must nevertheless be consistent with applicable employment, research and public-interest requirements.

Intellectual Property in Genetic Resources and Plant Biotechnology

China provides a specialised protection framework for new plant varieties through the Regulations on the Protection of New Varieties of Plants and related implementing rules. Eligible breeders may obtain protection for qualifying plant varieties, subject to statutory requirements.

Biotechnology involving human genetic resources is also subject to separate regulatory controls. Intellectual property rights do not automatically confer permission to collect, export, transfer or use regulated genetic resources. Researchers and companies must satisfy the applicable biosafety, ethical, data-protection and genetic-resource requirements independently of patent law.

Technology Transfer and Commercialisation

Biotechnology intellectual property supports licensing, research partnerships, joint ventures and commercial development. Licensing agreements should identify the protected technology, permitted uses, territorial scope, royalties, confidentiality obligations, improvements and responsibility for regulatory compliance.

Companies should also evaluate freedom to operate before commercialising a product. Holding a patent does not necessarily establish freedom to use another party's patented technology. Disputes may involve patent validity, infringement, ownership, licensing obligations or the misappropriation of confidential information.

Challenges and Future Development

China's biotechnology IP framework must address rapidly evolving fields such as synthetic biology, gene editing, artificial intelligence-assisted drug discovery and personalised medicine. Important challenges include defining patentable subject matter, ensuring adequate disclosure, evaluating experimental evidence and balancing proprietary rights against legitimate scientific research.

Effective protection requires predictable examination standards, consistent judicial interpretation, fair licensing practices and enforcement against unlawful appropriation. At the same time, public-health interests and lawful research activities must remain protected.

Conclusion

Intellectual property law is central to China's biotechnology innovation system. Patent law protects eligible technical inventions, trade-secret law safeguards confidential commercial knowledge, and specialised legislation provides additional protection for qualifying plant varieties and regulated biological activities. The engineered Sphingomonas patent case demonstrates the importance of reproducibility and sufficient disclosure, while the scientific research exception illustrates the need to balance patent rights with legitimate regulatory testing. A sound legal framework must encourage biotechnology investment while preserving scientific integrity, lawful research, fair competition and public welfare.